Suzanne Ildstad, Director at Talaris Therapeutics, Inc. (TALS), sold 115,733 shares at $2.33 ($266K) on 2023-04-20, disclosed to the SEC on 2023-04-21.
Scheduled sale ($266k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.16 | 21,753 | $47K | 17.7% |
| 2 | $2.33 | 46,990 | $109K | 41.2% |
| 3 | $2.33 | 46,990 | $109K | 41.2% |
| Total | $2.30 avg | 115,733 | $266K | 100% |
| Filing → |
| TALS | SELL | 2023-06-07 | $149K | — | Filing → |
| TALS | SELL | 2023-06-05 | $80K | — | Filing → |
| TALS | SELL | 2023-04-25 | $35K | — | Filing → |